Radius bolsters leadership with appointment of Novo Vet
pharmafile | July 18, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Novo Nordisk, Radius, biotech, drugs, pharma, pharmaceutical
Jesper Høiland has been revealed as the new President and Chief Executive Officer of Radius. The news comes shortly after it was revealed that Amgen’s rival osteoporosis drug had been rejected by the FDA.
The move to replace long-standing CEO, Bob Ward, was explained as a decision to bolster the company’s experience of successfully launching products into the market. Høiland has experience launching across the US, where he was responsible for the launch of four products in the preceding four years at Novo Nordisk.
Upon leaving Novo, Høiland had worked for the company close to 30 years – ending his time with the company as President and Executive Vice President of operations in the US. This experience will be called on for the launch of Radius’ drug Tymlos, a part of his role that he specifically referenced upon accepting the position.
“I am delighted to be joining Radius in the exciting, early stages of the commercialization of Tymlos,” said Jesper Høiland, “and I look forward to guiding the continued development of its strong pipeline. I am eager to work with our board, senior management and the entire organization to execute on our promising future and deliver on the Company’s long-standing goal of positively impacting the lives of patients and delivering significant value for all our stakeholders.”
Kurt Graves, Chairman of the Board, explained the decision to replace previous CEO, Ward, with Høiland: “We are pleased to welcome Jesper to Radius Health at this important time, and believe that he is uniquely qualified to lead Radius through the successful launch of Tymlos, and the advancement of our exciting clinical stage assets including elacestrant. Throughout his US and Global leadership roles at Novo Nordisk, he has demonstrated success in launching major brands, executing on business development and driving sustainable growth. His leadership and experience will be invaluable in guiding Radius through our next dynamic period of growth.”
Related Content
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
